Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

Clin Cancer Res. 2022 Jul 1;28(13):2972. doi: 10.1158/1078-0432.CCR-22-1596.
No abstract available

Publication types

  • Published Erratum